{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:01:36Z","timestamp":1784894496555,"version":"3.55.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2026,7,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Skin cancer, including melanoma and non-melanoma subtypes, remains a major global health challenge\nwith steadily rising incidence rates. Although conventional treatment modalities such as surgery, chemotherapy,\nradiotherapy, targeted therapy, and immunotherapy have improved patient outcomes, their clinical\neffectiveness is frequently limited by poor cutaneous penetration, systemic toxicity, non-specific drug distribution,\nand the emergence of drug resistance. In this context, lipid-based nanocarriers (LBNCs) have emerged\nas a promising strategy to address these therapeutic limitations. This comprehensive review highlights recent\nadvances in LBNCs, including liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers\n(NLCs), transferosomes, ethosomes, and invasomes, for the management of skin cancer. The review discusses\nthe physicochemical properties and mechanisms by which these nanocarriers enhance topical and transdermal\ndrug delivery by overcoming the stratum corneum barrier through hydration, lipid fluidization, and follicular\ntargeting. Furthermore, the role of LBNCs in achieving tumor-specific accumulation via passive targeting\nthrough the enhanced permeability and retention (EPR) effect, as well as active targeting using ligandfunctionalized\nsystems, is critically examined. Particular emphasis is placed on lipid nanoparticles as nonviral\nvectors for gene therapy, enabling the efficient delivery of nucleic acids such as siRNA, mRNA, and\nCRISPR\/Cas9 components to modulate oncogenic pathways. Recent preclinical and clinical developments,\nincluding personalized mRNA-based cancer vaccines, are summarized to demonstrate the translational potential\nof LBNCs. Overall, this review underscores the versatility of lipid-based nanocarriers as multifunctional,\nbiocompatible, and patient-friendly platforms, offering new opportunities for precise, effective, and personalized\nskin cancer therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113816128463662260612132215","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:10:42Z","timestamp":1784891442000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Harnessing Lipid-Based Nanocarriers for Skin Cancer Therapy: A Comprehensive Review of Drug Delivery, Gene-Based Strategies, and Clinical Translation"],"prefix":"10.2174","volume":"32","author":[{"given":"Viresh","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga, 142001, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Bharti","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga, 142001, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga, 142001, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113816128463662260612132215","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/256526\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113816128463662260612132215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:11:03Z","timestamp":1784891463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/256526\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113816128463662260612132215","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}